Xenon Pharmaceuticals Inc.XENENASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 2.76% |
| Q2 2025 | 22.52% |
| Q1 2025 | 2.91% |
| Q4 2024 | 4.39% |
| Q3 2024 | 14.62% |
| Q2 2024 | 12.32% |
| Q1 2024 | 7.73% |
| Q4 2023 | -4.21% |
| Q3 2023 | -2.63% |
| Q2 2023 | 11.45% |
| Q1 2023 | 13.45% |
| Q4 2022 | 18.34% |
| Q3 2022 | 32.90% |
| Q2 2022 | 14.39% |
| Q1 2022 | -11.55% |
| Q4 2021 | 15.86% |
| Q3 2021 | 2.80% |
| Q2 2021 | 12.69% |
| Q1 2021 | 8.96% |
| Q4 2020 | 14.73% |
| Q3 2020 | 21.69% |
| Q2 2020 | -9.08% |
| Q1 2020 | 0.33% |
| Q4 2019 | 20.52% |
| Q3 2019 | 18.84% |
| Q2 2019 | -10.20% |
| Q1 2019 | 42.63% |
| Q4 2018 | 2.66% |
| Q3 2018 | 15.38% |
| Q2 2018 | -3.08% |
| Q1 2018 | -12.77% |
| Q4 2017 | -10.71% |
| Q3 2017 | 17.27% |
| Q2 2017 | 3.49% |
| Q1 2017 | 34.28% |
| Q4 2016 | -26.30% |
| Q3 2016 | 16.89% |
| Q2 2016 | 16.93% |
| Q1 2016 | 2.37% |
| Q4 2015 | 12.39% |